SAM
FATE icon

Shell Asset Management’s Fate Therapeutics FATE Stock Holding History

Shell Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed – – 1265
2024
Q4 		$0 Hold
1
– – ﹤0.01% 1268
2024
Q3 		$0 Buy
+1
New +$4 ﹤0.01% 1253
2024
Q1 		$0 Sell
1
-59,301
-100% -$367K ﹤0.01% 1267
2023
Q4 		$222K Sell
59,302
-17,897
-23% -$42.2K 0.01% 815
2023
Q3 		$164K Buy
77,199
+73,456
+1,962% +$243K 0.01% 966
2023
Q2 		$18K Sell
3,743
-21
-0.6% -$116 ﹤0.01% 1261
2023
Q1 		$21K Sell
3,764
-13
-0.3% -$78 ﹤0.01% 1231
2022
Q4 		$38K Sell
3,777
-765
-17% -$14.4K ﹤0.01% 1291
2022
Q3 		$102K Sell
4,542
-1,190
-21% -$34.4K ﹤0.01% 1226
2022
Q2 		$142K Buy
5,732
+9
+0.2% +$248 ﹤0.01% 1205
2022
Q1 		$222K Sell
5,723
-848
-13% -$32.8K 0.01% 1143
2021
Q4 		$384K Buy
6,571
+36
+0.6% +$2.04K 0.01% 1012
2021
Q3 		$387K Sell
6,535
-290
-4% -$22.7K 0.01% 978
2021
Q2 		$592K Buy
+6,825
New +$550K 0.01% 843

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Shell Asset Management's FATE Position: Q1 2025 in Review

Shell Asset Management sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 1 share.

Shell Asset Management first reported a position in FATE in Q2 2021 and held it in 14 quarters. The position peaked at $592K in Q2 2021. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

  • Shell Asset Management reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Shell Asset Management sold 1 Fate Therapeutics share in Q1 2025.
  • Shell Asset Management first reported a position in Fate Therapeutics in Q2 2021 and held it in 14 quarters.
  • Shell Asset Management's Fate Therapeutics position peaked at $592K in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on Shell Asset Management's 13F filing for Q1 2025, filed 14 May 2025.